Group 1 - Aishalon (920050) will be listed on the Beijing Stock Exchange on January 21, and will simultaneously delist from the New Third Board [1] - The issuance price is set at 15.98 yuan per share, with a total of 16.9198 million shares issued, raising a total of 270 million yuan [1] Group 2 - Aishalon focuses on the medical health sector, primarily engaged in the research, production, and sales of disposable medical consumables for rehabilitation care and medical protection [3] - The company provides ODM/OEM services for internationally renowned medical device brands and has seven self-operated factories located in Jiangsu and Thailand [3] - Aishalon's products are exported to over 50 countries and regions, including Europe, America, Japan, South Korea, the Middle East, and Africa [3] Group 3 - Revenue projections for Aishalon are 574 million yuan, 575 million yuan, and 692 million yuan for the years 2022, 2023, and 2024, respectively [3] - The net profit attributable to the parent company is expected to be 62.8181 million yuan, 66.957 million yuan, and 80.7111 million yuan for the same years [3]

Group 1 - The new stock market is currently active, but short-term sentiment may be overheated, indicating potential local volatility risks [1][12] - Since the beginning of the year, the new stock sector has shown strong performance for two consecutive trading weeks, with a favorable atmosphere for buying [2][12] - The average increase of new stocks listed since 2025 is approximately 3.1%, with about 70.7% of new stocks showing positive returns [6][26] Group 2 - The average issuance price-to-earnings ratio for new stocks in January is 19.6X, slightly down from the previous month [13][15] - The average first-day closing price-to-earnings ratio for new stocks in January is 52.2X, down from 69.9X in the previous month [15][16] - The first-day average increase for new stocks in January is 138.8%, compared to 205.6% in the previous month, indicating a temporary decline in trading enthusiasm [16][24] Group 3 - Upcoming new stocks include Aisheren, Hengyun Chang, and Guoliang New Materials, with expected issuance price-to-earnings ratios of 44.1X for the new stocks [4][30] - The new stock issuance remains constrained, but the active funding environment suggests continued profit opportunities in new stock subscriptions [30][31] - Specific stocks recommended for attention include Tongyu New Materials, Fengbei Biological, and Hengkang New Materials, which are expected to show significant activity [39][40]

Group 1 - The core point of the news is that Hengyun Chang has issued 16.93 million shares at a price of 92.18 yuan, raising a total of 1.561 billion yuan, making it the highest fundraising company this year so far [1][2] - As of January 16, a total of 5 companies have gone public this year, raising a cumulative amount of 3.509 billion yuan, with an average fundraising of 702 million yuan per company [1] - The distribution of fundraising amounts shows that two companies raised over 1 billion yuan, while three companies raised below 500 million yuan [1] Group 2 - The average initial public offering (IPO) price this year is 30.49 yuan, with Hengyun Chang having the highest price at 92.18 yuan [2] - The geographical distribution of newly issued stocks is mainly concentrated in Zhejiang, Jiangsu, and Hebei, with Guangdong, Chongqing, and Jiangsu leading in fundraising amounts [2] - The detailed fundraising data for the companies includes Hengyun Chang (1.561 billion yuan), C Zhixin (1.240 billion yuan), Aisheren (270 million yuan), N Kema (244 million yuan), and Guoliang New Materials (194 million yuan) [2]

Group 1 - The core viewpoint of the article highlights the upcoming IPO of Aisheren, which is set to issue shares at a price of 15.98 yuan, with a total market value of 811 million yuan and a price-to-earnings ratio of 14.99 [2][3] - Aisheren is the largest manufacturer of medical care pads in China, with its main products accounting for 53.41% in rehabilitation care products and 45.76% in surgical infection control products [2][3] - The company has over 20 years of industry experience and has established partnerships with international groups such as Medline, which enhances its future business development prospects [2][3] Group 2 - The company reported a net profit of 691.64 million yuan for the past three years, with a projected growth of 20.36% for 2024 [3] - Revenue figures for the last three years include 574.66 million yuan in 2023 (up 0.19%) and 573.56 million yuan in 2022 [3] - The funds raised from the IPO will be directed towards the construction of the Caple Public Health Medical Supplies Industrial Park [3]

Investment Rating - The investment rating for the company is "Buy," indicating an expected relative increase of over 15% compared to the relevant market index within the next 6-12 months [37]. Core Insights - The company, Aisheren (920050.BJ), specializes in the research, production, and sales of disposable medical consumables in the rehabilitation and medical protection fields. It has established itself as a leading player in the domestic medical dressing industry and has significant competitive advantages in specific segments like medical care pads [2][30]. - The company reported revenues of CNY 574 million in 2022, with a slight growth forecast to CNY 691.6 million in 2024, representing a year-over-year growth of 20.36%. The net profit attributable to the parent company is expected to grow from CNY 63 million in 2022 to CNY 81 million in 2024, with a projected growth rate of 20.54% [8][4]. - The company has a strong partnership with Medline Group, which has been its largest customer since 2007, contributing over 70% of its revenue. This long-term relationship is expected to remain stable [30][31]. Financial Performance - The company achieved revenues of CNY 573.6 million, CNY 574.7 million, and CNY 691.6 million for the years 2022, 2023, and 2024, respectively, with year-over-year growth rates of 0.03%, 0.19%, and 20.36% [4][8]. - The net profit attributable to the parent company for the same years was CNY 62.8 million, CNY 67 million, and CNY 80.7 million, with year-over-year growth rates of -37.12%, 6.62%, and 20.54% [4][8]. Industry Overview - The medical dressing industry is a significant segment of the low-value medical consumables market, accounting for approximately 21%. The global market for medical dressings is projected to grow from USD 9 billion in 2011 to USD 23.5 billion by 2026, driven by increasing demand due to an aging population and rising healthcare expenditures [15][18]. - In China, the medical dressing market is expected to grow from CNY 7 billion in 2011 to CNY 33.3 billion by 2026, indicating a robust growth trajectory supported by improved healthcare infrastructure and rising health awareness among the population [20][18]. Competitive Positioning - Aisheren is positioned among the top ten domestic medical dressing companies and is the largest manufacturer of medical care pads in China. The company differentiates itself through a focus on product research and development, automation in production, and a global supply chain strategy [30][31]. - The company plans to expand its product line to include OTC products and medical collection bags, which are expected to enhance future revenue streams significantly [31][32]. Investment Projects - The company plans to invest CNY 30 million in the construction of a public health medical supplies industrial park, which aims to enhance production capacity and quality control [33][32].

IPO Review and Registration Progress - Two companies, Chenguang Electric and Banzhe Chuangke, were reviewed for IPO on the North Exchange, with a notable increase in IPO review frequency expected in 2025 [2][3] - Chenguang Electric reported revenue of 687 million yuan and a net profit of 68 million yuan for the first three quarters of 2025, focusing on micro-special motors for cleaning appliances [2][3] - Banzhe Chuangke's revenue for 2022 to 2025 was reported as 1.071 billion yuan, 1.168 billion yuan, 1.51 billion yuan, and 1.354 billion yuan, with net profits of 7.14 million yuan, 108 million yuan, 148 million yuan, and 121 million yuan respectively [3] Upcoming IPOs - Six companies are set to undergo IPO reviews this week, with Tianhai Electronics planning to raise 2.46 billion yuan, the highest among them [5] - Tianhai Electronics reported revenues of 8.215 billion yuan, 11.549 billion yuan, 12.523 billion yuan, and 10.898 billion yuan from 2022 to the first three quarters of 2025, with net profits of 402 million yuan, 652 million yuan, 614 million yuan, and 537 million yuan [5][6] - High-tech Electronics, focusing on new energy battery management systems, reported revenues of 346 million yuan, 779 million yuan, and 919 million yuan from 2022 to 2024, with net profits of 53.75 million yuan, 88.23 million yuan, and 98.42 million yuan [7] New Stock Listings and Subscription Dynamics - Shaanxi Tourism was listed on the Shanghai Main Board, with a first-day increase of 64.1%, closing at 132 yuan per share [9] - The company expects revenues of 951 million yuan to 1.117 billion yuan for 2025, with a projected decline of 24.69% to 11.54% [9] - Two new stocks, Aisheren and Hengyun Chang, are scheduled for subscription, with Aisheren's issue price set at 15.98 yuan per share [10][11]

Group 1 - The article discusses the stock issuance of a company named "爱舍伦" with a subscription limit of 761,300 shares and an issuance price of 15.98 yuan [1] - The industry price-earnings ratio is noted as 14.99, while the overall market price-earnings ratio stands at 29.79, indicating a potential valuation opportunity [1] Group 2 - There are no new bonds issued today, suggesting a stable bond market environment [2]

Core Viewpoint - Aishalon has initiated its public offering with an issuance price of 15.98 yuan and a price-to-earnings ratio of 14.99 times, aiming to raise a total of 270 million yuan for the construction of a public health medical supplies industrial park [1] Group 1: IPO Details - The issuance code for Aishalon is 920050, with a total issuance quantity of 16.9198 million shares and a post-issuance total share capital of 67.6793 million shares [1] - The online issuance volume is 15.2279 million shares, and the strategic placement shares total 1.6920 million shares, accounting for 10% of the initial issuance scale [1] - The maximum subscription limit for a single account is 761,300 shares [1] Group 2: Financial Performance - The projected net profits for Aishalon from 2022 to 2024 are 62.8015 million yuan, 66.9570 million yuan, and 80.7111 million yuan, reflecting year-on-year changes of -37.12%, 6.62%, and 20.54% respectively [1] - Key financial indicators for 2024 include total assets of 1,009.4344 million yuan, net assets of 726.9580 million yuan, and operating income of 691.6387 million yuan [2] - The net profit attributable to the parent company for 2024 is projected at 80.7111 million yuan, with a basic earnings per share of 1.59 yuan [2]

Group 1 - This week, two new stocks will be available for subscription: Aisheren on Monday and Hengyunchang on Friday [2][3] - Last week, a new stock, Shaanxi Tourism, debuted with a first-day increase of 64.1% [3] - Six companies are undergoing IPO review this week, including Gaote Electronics, Lianxun Instruments, Xingsheng Technology, Zhongke Instruments, and Tianhai Electronics [3][4] Group 2 - Lianxun Instruments, established in 2017 with a registered capital of 77 million yuan, focuses on the R&D, manufacturing, sales, and service of electronic measurement instruments and semiconductor testing equipment [3] - The company aims to raise 1.711 billion yuan through its IPO and is the second global company to launch core testing instruments for the highest level 1.6T optical modules [3] - Revenue projections for Lianxun Instruments from 2022 to the first three months of 2025 are 214 million yuan, 276 million yuan, 789 million yuan, and 201 million yuan, with net profits of -38.07 million yuan, -55.39 million yuan, 140 million yuan, and 19.33 million yuan respectively [3]

Group 1: New IPOs - This week (January 12 to 16), there are 2 new stocks available for subscription: one on the Sci-Tech Innovation Board and one on the Beijing Stock Exchange [1] - The Beijing Stock Exchange new stock Aisheren has an issue price of 15.98 yuan and a price-to-earnings ratio of 14.99, while the industry average dynamic P/E ratio over the past month is 29.3 [3] - Aisheren focuses on the medical health sector, specializing in the R&D, production, and sales of disposable medical consumables for rehabilitation care and medical protection [3] Group 2: Company Highlights - The Sci-Tech Innovation Board new stock Hengyun Chang is a leading supplier of core components for semiconductor equipment, particularly in the plasma RF power system, which is a critical part of the semiconductor supply chain [3][4] - Hengyun Chang has established a leading position in the domestic semiconductor industry, with a projected market share of 1st place among domestic manufacturers of plasma RF power systems in 2024 [4] - The company has strong customer relationships with major semiconductor equipment manufacturers, enhancing customer stickiness [4] Group 3: Financial Performance - Hengyun Chang's gross profit margins are projected to increase from 41.49% in 2022 to 48.51% in 2024, driven by a higher proportion of high-margin self-developed products [4] - The IPO proceeds will focus on capacity expansion and technological advancements, aiming to solidify the company's leading position in the semiconductor plasma RF power system sector [4] Group 4: Upcoming IPO Meetings - Six companies are scheduled for IPO meetings this week, including Tianhai Electronics, which focuses on automotive wiring harnesses and electronic components, aiming to raise 2.46 billion yuan [6][7] - Gaote Electronics, specializing in battery monitoring and management, plans to raise 850 million yuan through its IPO [6] - Lianxun Instruments, a leading provider of high-end testing instruments, aims to raise 1.711 billion yuan [6]